

業績目録（令和元年）

教室・部門名 呼吸器内科学

(A-a) 英文著書

なし

(A-b) 和文著書

1. 山田忠明,
EGFR 阻害薬（ゲフィチニブなど）. がん生物学 イラストレイテッド
2 pp. 339-343, 2019
2. 谷村恵子, 山田忠明, 千原佑介, 久保田豊, 塩津伸介, 竹田隆之,
山田崇央, 平沼修, 内野順治, 高山浩一
非小細胞肺癌の免疫チェックポイント阻害薬における自己免疫関連
有害事象と治療効果の関連についての検討. 肺癌 59:128-136, 2019
3. 内野順治, 高山浩一
「非小細胞肺癌(初期)」. 今日の診療サポート(オンライン) エルゼビ
ア, 2019

(B-a) 英文総説

なし

(B-b) 和文総説

1. 金子美子、瀬古友利恵、高山浩一
気管支喘息治療における分子標的治療について 京都府立医科大学雑
誌 128 (4), 255～ 263, 2019
2. 谷村 恵子, 内野 順治, 高山 浩一
【神経内分泌腫瘍の薬物療法】肺原発神経内分泌腫瘍に対する薬物療法
腫瘍内科 23(3) :221-227, 2019

(C-a) 英文原著

1. Takayama K, Ichiki M, Tokunaga S, Inoue K, Kawasaki M, Uchino
J, Nakanishi Y.
Randomized, phase II study of weekly paclitaxel plus
carboplatin versus biweekly paclitaxel plus carboplatin for
patients with previously untreated advanced non-small cell
lung cancer. Oncologist. pii: theoncologist.2019-0513, 2019

(IF=5.025)

2. Yamada T, Hirai S, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S, Kikuchi T, Hirose K, Kubota Y, Chihara Y, Harada T, Tanimura K, Takeda T, Tamiya N, Kaneko Y, Uchino J, Takayama K.
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. *Cancer Med.* 8: 1521–1529, 2019 (IF=3.491)
3. Iwasaku M, Uchino J, Yamada T, Chihara Y, Shimamoto T, Tamiya N, Kaneko Y, Kiyomi F, Takayama K.
Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study) *Transl Lung Cancer Res.* 8:519–523, 2019 (IF=5.132)
4. Iwasaku M, Tanaka S, Shinzawa M, Kawakami K.
Impact of underlying chronic adrenal insufficiency on clinical course of hospitalized patients with adrenal crisis: A nationwide cohort study. *Eur J Intern Med.* 64:24–28, 2019 (IF=4.329)
5. Imabayashi T, Uchino J, Osoreda H, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K
Nicotine induces resistance to erlotinib therapy in non-small-cell lung cancer cells treated with serum from human patients. *Cancers (Basel).* 11: 282, 2019 (IF=6.126)
6. Imabayashi T, Uchino J, Yoshimura A, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K
Safety and usefulness of cryobiopsy and stamp cytology for the diagnosis of peripheral pulmonary lesions. *Cancers (Basel).* 11: 410, 2019 (IF=6.126)
7. Yoshimura A, Chihara Y, Date K, Tamiya N, Takemura Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K.
Phase II study of S-1 and paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. *Oncologist.* 24: 459–e131, 2019 (IF=5.025)

8. Yoshimura A, Yamada T, Tsuji T, Hamashima R, Shiotsu S, Yuba T, Takumi C, Uchino J, Hiraoka N, Takayama K.
Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. *Thorac Cancer*. 10: 557-563, 2019 (IF=2.61)
9. Yoshimura A, Yamada T, Okura N, Takeda T, Hirose K, Kubota Y, Shiotsu S, Hiranuma O, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.
Clinical characteristics of osimertinib responder in non-small cell lung cancer patients with EGFR-T790M mutation. *Cancers (Basel)*. 11: 365, 2019 (IF=6.126)
10. Yoshimura A, Uchino J, Hasegawa K, Tsuji T, Shiotsu S, Yuba T, Takumi C, Yamada T, Takayama K, Hiraoka N.
Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. *Transl Lung Cancer Res*. 8:227-234, 2019 (IF=5.132)
11. Yoshimura A, Yamada T, Miyagawa-Hayashino A, Sonobe Y, Imabayashi T, Yamada T, Okada S, Shimamoto T, Chihara Y, Iwasaku M, Kaneko Y, Uchino J, Inoue M, Konishi E, Takayama K.
Comparing Three Different Anti-PD-L1 Antibodies for Immunohistochemical Evaluation of Small Cell Lung Cancer. *Lung Cancer*. 137:108-112, 2019 (IF=4.702) (呼吸器外科学、人体病理学との共同)
12. Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, Goto H, Yoneda H, Harada T, Kubota Y, Yamada T, Date K, Shiotsu S, Nagata K, Chihara Y, Kaneko Y, Uchino J, Nishioka Y, Takayama K.
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. *Transl Lung Cancer Res*. 8:450-460, 2019 (IF=5.132)
13. Yoshimura A, Chihara Y, Date K, Tamiya N, Takemura Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K.
A phase II study of S-1 and paclitaxel combination therapy

- as a first-line treatment in elderly patients with advanced non-small cell lung cancer. *The Oncologist*. 24:459-e131, 2019 (IF=5.025)
14. Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Goto H, Yoneda H, Kanematsu T, Kubota Y, Chihara Y, Harada T, Shiotsu S, Uchino J, Nishioka Y, Takayama K
Clinical significance of PD-L1 expression for patients with advanced non-small cell lung cancer treated with docetaxel and ramucirumab. *Transl Lung Cancer Res*. 8:450-460, 2019 (IF=5.132)
 15. Katayama Y, Yamada T, Tanimura K, Yoshimura A, Takeda T, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. *Thorac Cancer*. 10: 526-532, 2019 (IF=2.61)
 16. Onoi K, Kaneko Y, Uchino J.
Osimertinib in first line setting: for Asian patients. *Transl Lung Cancer Res*. 8:550-552, 2019. (editorial) (IF=5.132)
 17. Chihara Y, Date K, Takemura Y, Tamiya N, Kohno Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. *Invest New Drugs*. 37: 291-296, 2019 (IF=3.525)
 18. Chihara Y, Yoshimura A, Date K, Takemura Y, Tamiya N, Kohno Y, Imabayashi T, Takeuchi M, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K.
Phase II study of S-1 and paclitaxel combination therapy in patients with previously treated non-small cell lung cancer. *Oncologist*. 24:1033-e617, 2019 (IF=5.025)
 19. Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino

J, Uehara H, Takayama K, Yano S.

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. *Nat Commun.* 10: 259, 2019 (IF=12.121)

20. Sakakida T, Ishikawa T, Uchino J, Chihara Y, Komori S, Asai J, Narukawa T, Arai A, Kobayashi T, Tsunozuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K.

Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. *Oncology Letters* 18: 2140-2147, 2019 (IF=2.311)

21. Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunozuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K.

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.

Clin Transl Oncol. doi: 10.1007/s12094-019-02214-8, 2019 (IF=2.737)

22. Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Kita T, Hiraoka N, Ishizuka T, Kubota Y, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K.

Osimertinib in elderly patients with epidermal growth factor receptor T790M-positive non-small-cell lung cancer who progressed during prior treatment: a phase II trial. *Oncologist.* 24: 593-e170, 2019 (IF=5.025)

23. Hiranuma O, Uchino J, Yamada T, Chihara Y, Tamiya N, Kaneko Y, Yoshimura K, Takayama K.

Rationale and design of a phase II trial of osimertinib combined with bevacizumab in patients with untreated epidermal growth factor receptor-mutated non-small-cell lung cancer and malignant pleural and/or pericardial effusion

- (SPIRAL II Study). *Clin Lung Cancer*. 20: e402–e406, 2019 (IF=3.550)
24. Nishioka N, Uchino J, Hirai S, Katayama Y, Yoshimura A, Okura N, Tanimura K, Harita S, Imabayashi T, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.
Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer. *J. Clin. Med.* 8: 450, 2019 (IF=3.303)
25. Kitagawa C, Iwasaku M, Kogure Y, Ando M, Yoshioka H, Nishiyama A, Watanabe N, Kunimasa K, Tsubouchi K, Oka S, Saka H.
Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer. *In Vivo*. 33(1):163–166, 2019 (IF=1.541)
26. ○Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S
Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. *Cancer Res*. 79:1658–1670, 2019 (IF=9.727)
27. ○Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, Yano S
Distribution and activity of lenvatinib in brain tumors models of human anaplastic thyroid cancer cells in severe combined immune deficient mice. *Mol Cancer Ther*. 18:947–956, 2019 (IF=5.615)
28. ○Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP
The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non-small cell lung cancer. *J Thorac Oncol*. 14:1061–1076, 2019 (IF=13.357)
29. Kanazawa J, Kitazawa H, Masuko H, Yatagai Y, Sakamoto T, Kaneko Y, Iijima H, Naito T, Saito T, Noguchi E, Konno S, Nishimura M, Hirota T, Tamari M, Hizawa N.

A cis-eQTL allele regulating reduced expression of CHI3L1 is associated with late-onset adult asthma in Japanese cohorts. BMC Med Genet. 2;20(1):58.2019 (IF=1.585)

(C-b) 和文原著

なし

(D) 学会発表

I) 特別講演、教育講演等

1. 高山浩一

進行肺がんの薬物療法-複合免疫療法の時代-

第59回臨床呼吸機能講習会 2019年8月 京都

II) シンポジウム、ワークショップ、パネルディスカッション等

1. 山田忠明、高山浩一.

EGFR変異肺がんのEGFR阻害薬における初期治療抵抗性機構の解明

第23回日本がん分子標的治療学会学術集会 2019年6月 大阪

III) 国際学会における一般発表

1. Yamada T, Takayama K

The efficacy of a Histone deacetylase inhibitor in combination with a MEK inhibitor in lung cancer cells harboring RAS mutations
The 2nd International Cancer Research Symposium of Training Plan for Oncology Professionals, 2019 February 2-3, Osaka

2. Yamada T, Hirai S, Yoshimura A, Watanabe S, Uchino J, Takayama K

The efficacy of immune checkpoint inhibitors in patients with EGFR mutated non small cell lung cancer in retrospective analysis
AACR Annual Meeting 2019, 2019 March 29-April 3;Atlanta, USA

3. Yoshimura A, Yamada T, Okura N, Uchino J, Takayama K

Impact of the EGFR-T790M mutation detection by re-biopsy in EGFR mutant NSCLC patients in the retrospective analysis
AACR Annual Meeting 2019, 2019 March 29-April 3;Atlanta, USA

4. Kaneko Y, Mouri T, Tamiya N, Yamada T, Uchino J, Takayama K

Search for prognosis prediction factors in treatment selection for elderly patients with EGFR negative advanced stage non-small

cell lung cancer patients

AACR Annual Meeting 2019, 2019 March 29-April 3; Atlanta, USA

5. Kawashima Y, Yamaguchi O, , Kozuki T, Furuya N, Kurimoto F, Okuno T, Yamada T, Komiyama K, Ko R, Nagai Y, Ishikawa N, Harada T, Watanabe K, Seike M, Yoshimura K, Kobayashi K, Kagamu H
Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
ESMO2019, 2019, September 27- October 1; Barcelona, Spain

E 研究助成（競争的研究助成金）

総額 675 万円（全ての小計の合計）

公的助成

高山浩一

代表 小計 80 万円

1. AMED 革新的がん医療実用化研究事業

悪性腫瘍に伴う悪液質の標準治療の確立フォローアップ研究 令和元年度
助成金額 80 万円

分担（総額 150 万円）・小計 50 万円

2. 文部科学省科学研究費補助金 基盤研究（B） 平成 29 年～令和元年度

患者由来がん組織を培養可能なデバイスの開発とがん免疫療法の評価法の
構築

助成金額 50 万円

山田忠明

代表・（総額 330 万円）小計 90 万円

1. 文部科学省科学研究費 基盤研究（C） 令和元年度～令和 3 年度

肺がんの「治療抵抗に関わるシグナル指向性」を標的とした画期的治療・
診断法の開発

助成金額 90 万円

分担（総額 5 万円） 小計 5 万円

- 2 文部科学省科学研究費補助金 基盤研究(C) 令和元年度～令和3年度
Nanometer scale resolution imaging of pH and reactive oxygen species on the outer membrane surface for fast and effective cell discrimination in cancer tissues.
助成金額 5 万円

代表（総額 30 万円） 小計 30 万円

3. 金沢大学がん進展制御研究所 令和元年度
肺癌における分子標的治療薬の治療抵抗性細胞の解明とその克服治療法の開発

金子美子

代表（総額 320 万円） 小計 130 万円

1. 文部科学省科学研究費 若手研究 平成 30 年度～令和元年度
NSAIDs 内服で惹起される好酸球性炎症と PGE2/EP3 遺伝子多型に関する検討
助成金額 130 万円

分担（総計 100 万円） 小計 40 万円

2. 厚生労働省科学研究費 平成 30 年度～令和 2 年度
アレルギー疾患の患者および養育者の就労・就学支援を推進するための研究
助成金額 40 万円

財団等からの助成

山田忠明

代表 小計 50 万円

1. 公益信託癌臨床研究助成基金 令和元年度～令和 2 年度
小細胞肺がんの腫瘍内 PD-L1 発現に関する最適診断法の開発
助成金額 50 万円

金子美子

代表 小計 200 万円

1. 公益財団法人難病医学研究財団 平成 30 年度～令和 3 年度
平成 30 年度医学研究奨励助成事業
助成金額 200 万円